Myomo, Inc.

BST:0M61 Stock Report

Market Cap: €186.6m

Myomo Valuation

Is 0M61 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0M61 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 0M61's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 0M61's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0M61?

Key metric: As 0M61 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 0M61. This is calculated by dividing 0M61's market cap by their current revenue.
What is 0M61's PS Ratio?
PS Ratio7.7x
SalesUS$25.24m
Market CapUS$194.18m

Price to Sales Ratio vs Peers

How does 0M61's PS Ratio compare to its peers?

The above table shows the PS ratio for 0M61 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average2.2x
PUS PULSION Medical Systems
3.7xn/a€133.6m
SBS Stratec
1.4x7.7%€361.6m
EUZ Eckert & Ziegler
3.3x5.4%€928.9m
DRW3 Drägerwerk KGaA
0.3x4.2%€805.2m
0M61 Myomo
7.7x23.2%€194.2m

Price-To-Sales vs Peers: 0M61 is expensive based on its Price-To-Sales Ratio (7.7x) compared to the peer average (2.2x).

Price to Sales Ratio vs Industry

How does 0M61's PS Ratio compare vs other companies in the DE Medical Equipment Industry?

4 CompaniesPrice / SalesEstimated GrowthMarket Cap
DRW3 Drägerwerk KGaA
0.3x4.2%US$838.10m
PHH2 Paul Hartmann
0.3xn/aUS$824.35m
U4W0 Quotient
0.07xn/aUS$2.78m
MF6 MagForce
0.3xn/aUS$404.27k
No more companies available in this PS range
0M61 7.7xIndustry Avg. 3.4xNo. of Companies4PS01.63.24.86.48+
4 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: 0M61 is expensive based on its Price-To-Sales Ratio (7.7x) compared to the European Medical Equipment industry average (3.4x).

Price to Sales Ratio vs Fair Ratio

What is 0M61's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0M61 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio7.7x
Fair PS Ratio3.3x

Price-To-Sales vs Fair Ratio: 0M61 is expensive based on its Price-To-Sales Ratio (7.7x) compared to the estimated Fair Price-To-Sales Ratio (3.3x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 0M61 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€5.65
€7.30
+29.3%
13.9%€8.58€5.72n/a6
Dec ’25€5.03
€6.91
+37.3%
12.2%€8.48€5.65n/a6
Nov ’25€3.44
€6.39
+86.0%
13.3%€7.71€5.22n/a6
Oct ’25€3.48
€6.39
+83.6%
13.3%€7.71€5.22n/a6
Sep ’25€3.94
€6.39
+62.1%
13.3%€7.71€5.22n/a6
Aug ’25€4.14
€6.31
+52.4%
12.6%€7.62€5.31n/a6
Jul ’25€2.83
€6.08
+115.1%
15.3%€7.60€4.83n/a5
Jun ’25€3.14
€6.08
+93.5%
15.3%€7.60€4.83n/a5
May ’25€3.03
€5.83
+92.8%
18.4%€7.39€4.39n/a4
Apr ’25€3.14
€5.83
+85.7%
18.4%€7.39€4.39n/a4
Mar ’25€2.84
€5.45
+92.0%
21.0%€7.09€4.21n/a4
Feb ’25€3.04
€5.45
+79.3%
21.0%€7.09€4.21n/a4
Jan ’25€4.76
€5.45
+14.5%
21.0%€7.09€4.21n/a4
Dec ’24€3.00
€4.49
+49.7%
39.8%€7.10€2.06€5.034
Nov ’24€1.09
€3.02
+176.8%
73.1%€6.83€1.59€3.444
Oct ’24€1.05
€3.02
+187.3%
73.1%€6.83€1.59€3.484
Sep ’24€0.74
€3.02
+305.0%
73.1%€6.83€1.59€3.944
Aug ’24€0.64
€3.06
+377.7%
76.7%€7.12€1.56€4.144
Jul ’24€0.43
€3.69
+765.8%
65.1%€7.47€1.63€2.835
Jun ’24€0.50
€3.69
+640.6%
65.1%€7.47€1.63€3.145
May ’24€0.52
€4.18
+704.5%
62.0%€7.79€1.60€3.034
Apr ’24€0.65
€4.18
+548.6%
62.0%€7.79€1.60€3.144
Mar ’24€0.58
€4.62
+689.4%
55.2%€8.27€1.47€2.844
Feb ’24€0.45
€4.62
+921.7%
55.2%€8.27€1.47€3.044
Jan ’24€0.39
€7.76
+1,911.4%
63.7%€15.48€3.39€4.764
Dec ’23€0.69
€7.76
+1,033.5%
63.7%€15.48€3.39€3.004

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/26 20:37
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Myomo, Inc. is covered by 9 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Benjamin HaynorAlliance Global Partners
Scott HenryAlliance Global Partners
Edward WooAscendiant Capital Markets LLC